Aptar

Aptar Pharma, a global leader in drug delivery, dosing and protection technologies and services, today announced a new research collaboration with Macquarie University under an Australian Research Council (ARC) Linkage Project. The three-year program, “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” (ARC LP250100089), will investigate formulation approaches designed to support the pulmonary delivery of biologic medicines.

Aptar Beauty announces the first launch to market of its Nomad Refill fragrance packaging innovation with the new BVLGARI Le Gemme Tygar travel spray. Custom-engineered to pair refined aesthetics with practical functionality, it combines a sophisticated outer casing topped with a marble cap and gold metallic details, and a refillable 10 ml glass vial. Designed as a true objet d’art, this new launch brings together luxury aesthetics and intuitive refill gesture in a convenient on-the-go format.

How Can Human Imaging Improve Confidence in Nose-to-Brain Drug Development? Nose-to-brain (N2B) drug delivery has long attracted interest as a non-invasive approach for delivering therapies to the central nervous system (CNS). Yet as the field advances beyond proof of concept, developers face a critical challenge: understanding how reliably therapies reach their intended targets and how delivery performance influences clinical outcomes.

In this interview, Edouard Pagnoud, Product Line Manager for Vial Stoppers at Aptar Pharma, discusses the evolving expectations for elastomeric closures under USP <382>. He explains the importance of evaluating closures as part of the complete Container Closure System (CCS) and how system-level performance data can help pharmaceutical manufacturers develop robust, risk-informed qualification strategies for sterile injectable products.

Global leader in dispensing systems Aptar Beauty expands its Advance Collection, a new generation of all-plastic pumps designed to maximize recyclability. First introduced in 2025, the Advance dispensing solutions are suitable with the main plastic recycling streams while preserving the iconic design, dispensing quality and consumer experience of our best-selling products.

Crystal Lake, Illinois, September 14, 2026 - AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery.

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the successful transfer and commissioning of its Aptar Pharma Preservative Free (APF) production line at its manufacturing facility in Berazategui, Argentina.

Today's beauty market is defined by speed-to-market and high consumer expectations across all product categories. Once confined to the premium and luxury markets, custom packaging is now emerging as a powerful lever for all brands. This white paper serves as a guide for brands looking to differentiate themselves on shelf, reinforce their brand equity, and deliver their creative vision through unique packaging and memorable user experience.

Today, Aptar, a global leader in drug delivery and consumer product dispensing, dosing and protection technologies participated in the Wells Fargo Healthcare Conference in Boston. During the conference, Gael Touya, President and CEO, reinforced Aptar’s strategic priorities for creating long-term value, including strengthening customer partnerships through innovation and expertise and delivering long-term value for stakeholders.

Optimising Preclinical Studies for Intranasal and Pulmonary Programmes Pharmaceutical Publications